Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy, marking a first for the “off-the-shelf” cell therapy tech.

After welcoming Shockwave Medical to its stable of medtech businesses earlier this year, Johnson & Johnson reported that its new acquisition had slightly bumped up its sales growth for the quarter.

Three months after The Column Group acquired NGM Bio to take the biotech private, the VC firm has overseen a $122 million fundraise to fuel clinical trials of NGM’s two lead assets.

Roche’s $2.7 billion bet on Carmot Therapeutics has delivered another early win. Participants in a phase 1 trial lost 7.3% of their body weight after taking Carmot’s oral GLP-1 prospect for four weeks, suggesting the candidate can hold its own against rival molecules from the likes of Eli Lilly and Pfizer.

A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and didn’t hint at any plans to pause this work to conserve cash.

Actuate Therapeutics has set out plans for a modest $52 million IPO as the biotech seeks to fund a pair of trials for its glycogen synthase kinase‐3 beta (GSK-3β) drug.

As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel.

Sotio has struck a deal to fuse bispecifics with its antibody-drug conjugate (ADC) capabilities, agreeing to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to targeting molecules.

Vertex struck gold with the licensing of CRISPR Therapeutics’ sickle cell gene editing therapy in 2017. With that med now approved as Casgevy, Vertex is looking to extend its claim in gene editing therapy through a small licensing deal with South Korea’s Orum.

On the heels of early-stage data for monoclonal antibody visugromab showing “impressive and lasting responses” among patients with difficult to treat cancers, CatalYm has secured a $150 million series D.